Video Interview with Massimo Radaelli
John E. Kaye
News & Features
- Published
- Videos
Noventia Pharma is a speciality pharmaceutical Company based in Milano, Italy. Founded in 2009 and with operations in Southern Europe, Noventia’s focus is the research, development, and marketing of Orphan Drugs.
Massimo Radaelli is the Founder, President and CEO of Noventia Pharma, and also the CEO and Board Member of Napo Therapeutics. Both companies have Rare Diseases as their primary focus.
TOP STORIES
-
Chinese education group to buy Dublin Business School for US$127.5m -
Germany could run on full renewables by 2045, study reveals -
Marriott signs all-inclusive resort deals in Jamaica and Zanzibar
-
AI takes majority of European venture funding as money floods into few firms
-
Rewilding improves wellbeing and community connection, charity report says
-
RABAM raises $500,000 ahead of Series A round
-
Prologis agrees £14.3bn takeover of UK warehouse group Segro
-
Germany’s former coal heartland makes pitch as Europe’s next AI hub
-
Iran war shock hits Eurozone spending twice as hard as expected
-
Spain urges EU rules as Chinese factories move in
-
Shell earnings more than double as Middle East conflict lifts energy prices
-
Deutsche Bank profits rise as trading business booms
-
Europe’s worst wildfires in modern times could cost billions
-
The European Summer 2026 edition – out now
-
British buyers fuel Greek luxury property boom after non-dom tax change
-
New York named world’s most attractive city for tourists
-
Saab lands German frigate deal after Poland submarine order
-
Students unveil world’s first solar-powered ambulance
-
Burnham told to tackle Britain’s cyber weak spots on day one
-
Doctors using AI before health systems set the rules
-
Humanoid robots could become the next K-pop stars
-
Hormuz flashpoint keeps global shipping on high alert
-
Scientists to gather in Lisbon to tackle next pandemic threats
-
Burnham warned digital exclusion is now a national security risk
-
Masts from Kent ‘doomsday wreck’ to be cut to prevent catastrophic explosion
Video Interview with Massimo Radaelli
John E. Kaye
News & Features
- Published
- Videos
Noventia Pharma is a speciality pharmaceutical Company based in Milano, Italy. Founded in 2009 and with operations in Southern Europe, Noventia’s focus is the research, development, and marketing of Orphan Drugs.
Massimo Radaelli is the Founder, President and CEO of Noventia Pharma, and also the CEO and Board Member of Napo Therapeutics. Both companies have Rare Diseases as their primary focus.
TOP STORIES
-
Chinese education group to buy Dublin Business School for US$127.5m
-
Germany could run on full renewables by 2045, study reveals
-
Marriott signs all-inclusive resort deals in Jamaica and Zanzibar
-
AI takes majority of European venture funding as money floods into few firms
-
Rewilding improves wellbeing and community connection, charity report says
-
RABAM raises $500,000 ahead of Series A round
-
Prologis agrees £14.3bn takeover of UK warehouse group Segro
-
Germany’s former coal heartland makes pitch as Europe’s next AI hub
-
Iran war shock hits Eurozone spending twice as hard as expected
-
Spain urges EU rules as Chinese factories move in
-
Shell earnings more than double as Middle East conflict lifts energy prices
-
Deutsche Bank profits rise as trading business booms
-
Europe’s worst wildfires in modern times could cost billions
-
The European Summer 2026 edition – out now
-
British buyers fuel Greek luxury property boom after non-dom tax change
-
New York named world’s most attractive city for tourists
-
Saab lands German frigate deal after Poland submarine order
-
Students unveil world’s first solar-powered ambulance
-
Burnham told to tackle Britain’s cyber weak spots on day one
-
Doctors using AI before health systems set the rules
-
Humanoid robots could become the next K-pop stars
-
Hormuz flashpoint keeps global shipping on high alert
-
Scientists to gather in Lisbon to tackle next pandemic threats
-
Burnham warned digital exclusion is now a national security risk
-
Masts from Kent ‘doomsday wreck’ to be cut to prevent catastrophic explosion
